(R)-N-(1-{1-[4-((2R,5S)-2,5-dimethylpyrrolidine-1-carbonyl)-2-fluorophenyl]ethylcarbamoyl}cyclopropyl)-3-fluoro-5-trifluoromethylbenzamide | 1134773-72-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-N-(1-{1-[4-((2R,5S)-2,5-dimethylpyrrolidine-1-carbonyl)-2-fluorophenyl]ethylcarbamoyl}cyclopropyl)-3-fluoro-5-trifluoromethylbenzamide
• 英文别名: N-(1-((R)-1-(4-((2R,5S)-2,5-dimethylpyrrolidine-1-carbonyl)-2-fluorophenyl)ethylcarbamoyl)cyclopropyl)-3-fluoro-5-(trifluoromethyl)benzamide；N-[1-[[(1R)-1-[4-[(2R,5S)-2,5-dimethylpyrrolidine-1-carbonyl]-2-fluorophenyl]ethyl]carbamoyl]cyclopropyl]-3-fluoro-5-(trifluoromethyl)benzamide
• CAS: 1134773-72-0
• 化学式: C₂₇H₂₈F₅N₃O₃
• 分子量: 537.53
• InChiKey: RQYSIEFGWQGKSD-OWCLPIDISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  38
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  78.5
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3-fluoro-4-[(1R)-1-[[1-[[3-fluoro-5-(trifluoromethyl)benzoyl]amino]cyclopropanecarbonyl]amino]ethyl]benzoic acid 、 cis-2,5-dimethylpyrrolidine 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (R)-N-(1-{1-[4-((2R,5S)-2,5-dimethylpyrrolidine-1-carbonyl)-2-fluorophenyl]ethylcarbamoyl}cyclopropyl)-3-fluoro-5-trifluoromethylbenzamide
  参考文献：
  名称：

  Novel small molecule bradykinin B1 receptor antagonists. Part 1: Benzamides and semicarbazides

  摘要：

  The synthesis and SAR of two series of bradykinin B-1 receptor antagonists is described. The benzamide moiety proved to be a suitable replacement for the aryl ester functionality of biaryl based antagonists. In addition, it was found that semicarbazides can effectively replace cyclopropyl amino acids. The compounds with the best overall pro. le were biaryl semicarbazides which display high antagonistic activity, low Caco-2 efflux and high oral bioavailability in the rat. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.119

文献信息

• TETRAZOLYL-CONTAINING CYCLOPROPANECARBOXAMIDES
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20190177284A1

  公开（公告）日：2019-06-13

  The present invention relates to tetrazolyl-containing cyclopropanecarboxamides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及一般式（I）所述的含四唑基环丙基甲酰胺化合物，以及包含该化合物的药物组合物和药物组合物，以及使用该化合物制备用于治疗或预防疾病的药物组合物，特别是神经源性障碍的药物组合物，作为唯一药剂或与其他活性成分结合使用。
• CARBOXYLIC ACID AROMATIC 1,2-CYCLOPROPYLAMIDES
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：US20190177279A1

  公开（公告）日：2019-06-13

  The present invention relates to carboxylic acid aromatic 1,2-cyclopropylamides of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及通式（I）所述和定义的芳香羧酸环丙胺酰胺，涉及包含该化合物的药物组合物和组合物，以及利用该化合物制备用于治疗或预防疾病的药物组合物，特别是神经源性疾病，作为唯一药剂或与其他活性成分组合使用。
• SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS
  申请人：Jerini AG

  公开号：EP2195288A2

  公开（公告）日：2010-06-16
• TETRAZOLE CONTAINING COMPOUNDS
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20210317092A1

  公开（公告）日：2021-10-14

  The present invention relates to tetrazole containing compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease syndrome, condition, or symptoms, in particular related to chronic pain and inflammation, as a sole agent or in combination with other active ingredients.
• [EN] SMALL MOLECULE BRADYKININ B1 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTE DE FAIBLE MASSE MOLÉCULAIRE DU RÉCEPTEUR B1 DE LA BRADYKININE
  申请人：JERINI AG

  公开号：WO2009036996A2

  公开（公告）日：2009-03-26

  Disclosed are compounds of formula (I) which are bradykinin B1 receptor (B1R) antagonists. These compounds are useful to treat diseases or relieve adverse symptoms associated with inflammation and pain. The invention encompasses novel compounds and acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases involving inflammation and pain.